2024-11-17 - Analysis Report
## Johnson & Johnson (JNJ) Stock Review

**1. Performance vs. S&P 500 (VOO):**

Johnson & Johnson (JNJ), a global healthcare company producing medical devices, pharmaceuticals, and consumer goods, has significantly underperformed the S&P 500 (VOO) over the analyzed period.  While JNJ shows a cumulative return of 35.02%, VOO boasts a return of 123.86%. This represents a difference of -88.84%, placing it at the 4.89th percentile of its historical performance relative to the S&P 500.  The provided data indicates substantial underperformance compared to the broader market.


**2. Recent Price Movement:**

* **Closing Price:** $154.0
* **5-Day Moving Average:** $153.36
* **20-Day Moving Average:** $158.62
* **60-Day Moving Average:** $161.91

The stock price is currently trading below its 5, 20, and 60-day moving averages, suggesting a downtrend.

**3. Technical Indicators & Expected Return:**

* **RSI (24.43):**  Indicates the stock is in oversold territory, potentially suggesting a bounce.
* **PPO (-0.42):**  Negative value suggests bearish momentum.
* **Relative Strength Change (20-day): -2.82:** Shows a recent weakening in relative strength.
* **Expected Return (0.0%):**  The model predicts no significant excess return over the S&P 500 for long-term (2+ years) investment at the current price.  This is consistent with the historical underperformance observed.  A price of $154.02 doesn't trigger any significant alerts of sudden jumps or drops; it aligns with the current downtrend.

**4. Recent Earnings and Outlook:**

The provided earnings data shows some volatility in EPS and relatively stable revenue.  There's no explicit comparison to analyst expectations for the most recent quarter (2024-10-23).  A complete analysis requires comparing reported EPS to analyst consensus estimates to determine whether the results beat or missed expectations.  Further information is needed for a comprehensive outlook.


| Date       | EPS   | Revenue (B$) |
|------------|-------|--------------|
| 2024-10-23 | 1.12  | 22.47        |
| 2024-07-25 | 1.95  | 22.45        |
| 2024-05-01 | 1.35  | 21.38        |
| 2024-02-16 | 1.68  | 21.39        |
| 2023-10-27 | 10.32 | 21.35        |


**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue remains relatively stable, with profit margins consistently high (around 69%).
* **Capital and Profitability:** ROE fluctuates, suggesting varying levels of profitability depending on the quarter. The exceptionally high ROE in 2023-09-30 requires further investigation to understand the contributing factors.

**6. News and Recent Issues:**

*This section requires accessing recent news sources like Shacknews and FINBOLD within the last two days to provide an up-to-date analysis of earnings news, market outlook, analyst opinions, and performance highlights.*  The absence of this information prevents a thorough assessment of current market sentiment.

**7. Overall Analysis (Summary of 1-6):**

JNJ has significantly underperformed the S&P 500, showing a substantial negative alpha.  Technical indicators suggest oversold conditions, but the negative PPO and downtrend in moving averages paint a cautious picture.  While profit margins are high and revenue is stable, recent EPS numbers show volatility. The missing context from recent news and a detailed comparison to earnings estimates prevents a definitive conclusion.  The model's prediction of zero excess return aligns with historical underperformance, suggesting caution regarding future prospects unless substantial positive catalysts emerge.


**8.  Recommendations:**

Based on the limited data available, a neutral stance is recommended.  The significant underperformance compared to the market, concerning technical indicators, and the need for further analysis of recent earnings reports and market sentiment suggest a wait-and-see approach. Before any investment decision, thorough due diligence including a comparison of the recent earnings against analyst estimates and a review of recent news, is crucial.  The model's projection of zero excess return is a significant factor to consider.
